Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-O: Roll Over Study for Olaparib in Oncology Patients
NCT04421963Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, breast cancer, sponsored by AstraZeneca. Started Aug 2020; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT04421963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421963.